Pharmaceuticals company Marksans Pharma announced Q1FY24 results:
- Operating revenue was Rs 500.0 crore, up by 15.3% YoY driven by market share gains in the existing products and markets
- US business grew by 11.2% YoY
- UK and Europe grew by 24.8% YoY
- Gross profit was Rs 257.3 crore, up by 17.5% YoY with a Gross margin of 51.5%.
- EBITDA was Rs 102.0 crore, grew by 39.9% with an EBITDA margin of 20.4%
- EPS grew by 3.8% YoY to Rs 1.52
- RoW business reported Rs 22.2 crore in Q1FY24
- In Q1FY24, the capex incurred was Rs 81.5 crore Capex investment is in-line with our plan for scaling the acquired manufacturing unit from Teva Pharma in Goa
- Cash Balance at the end of June 30, 2023 is at Rs 636 crore in Q1FY24
- In Q1FY24, Cash from Operations is at Rs 49.8 crore